3/20/2023 0 Comments Measurement computing instacal![]() recently developed a new methodological approach for increasing the selective response of cellular sensors against specific viral proteins. The assay is based on a specific interaction between the examined virus protein and the immobilized mammalian cells of the sensor causing the change of the electric potential across the cell membrane. as a novel method for the detection of plant and human viruses. The sensors were based on the Bioelectric Recognition Assay (BERA), originally developed by Kintzios et al. In the present report, novel cell sensors were developed for the detection of HBV and anti-HBs in clinical samples. Representing the most advanced (and complicated) biosensor technology, cell-based sensors utilize the measurement of whole cell responses to target compounds, such as oxygen consumption, surface chemical or electrical potential, mobility or genetic activity. Detection of HBV antibodies in serum has been facilitated by surface plasmon resonance (SPR) and chemiluminescent immunoassays. Electrochemical sensors voltametrically detect DNA sequences related to HBV, while sequence-specific detection has also been achieved by piezoelectric sensors and impedance spectroscopy. Various technologies have been used for this purpose. In recent years there has been a rapid increase in the number of diagnostic applications for HBV based on biosensors. Nucleic acid technologies are quite specific and sensitive but require time and investment in laboratory infrastructure and staff training. In particular, automated immunochemical systems are characterized by high throughput and selectivity, but often compromising sensitivity and speed, with the time required to get results ranging from 2 to 26 days. The fast detection of hepatitis viruses is still a challenging issue for the developers of diagnostic systems, facing challenges associated with increasing demands, difficulties in recruiting an appropriately skilled work force and pressure to improve turnaround times. For example, a person negative for HBsAg and positive for anti-HBs may have cleared an infection or a vaccination has taken place. The perspectives for using the novel biosensor as a qualitative, rapid screening, high throughput assay for HBV antigens and anti-HBs in clinical samples is discussed.ĭue to the complexity of the infection process the evaluation of the test results is not always an easy procedure. Fluorescence microscopy observations showed that attachment of HBV particles to cells membrane-engineered with anti-HBs was associated with a decrease of cyt. The observed response was rapid (45 sec) and quite reproducible. ![]() ![]() Detection of anti-HBs antibodies was made possible by using a biosensor based on immobilized Vero cells bearing the respective antigen (HBsAg). Considerably higher sensor responses were observed against HBV-positive samples, compared with responses against negative samples or samples positive for heterologous hepatitis viruses such as Hepatitis C (HCV) virus. The sensor was used for screening 133 clinical blood serum samples according to a double-blind protocol. The attachment of a homologous antigen to the electroinserted antibody (or, respectively, of the antibody to the electroinserted antigen) triggered specific changes to the cell membrane potential that were measured by appropriate microelectrodes, according to the principle of the Bioelectric Recognition Assay (BERA). The membrane-engineering process involved the electroinsertion of anti-HBV specific antibodies (anti-HBs, anti-HBe) or antigens (HBsAg) in the membranes of the Vero cells. The biosensor is based on “membrane-engineered” Vero fibroblast cells immobilized in an alginate matrix. A novel miniature cell biosensor detection system for the detection of Hepatis B virus (HBV)-associated antigens and anti-HBV is described.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |